# Adis

> Adis is a leading international publisher of drug-focused content, part of Springer Nature. The portfolio covers over 30 peer-reviewed medical journals spanning all therapeutic areas, plus the Reactions Weekly drug-safety newsletter.

Adis publishes across three journal models: **Premier** titles with full peer review and wide indexing, **Rapid+** titles offering the same rigour with decisions in as little as two weeks, and **Open Access** titles. Many journals belong to more than one model. Adis also produces Adis Drug Reviews — concise, evidence-based reviews of newly approved medicines — and offers publishing services to industry, including medical writing, digital features and enhanced content.

Journal content is hosted on SpringerLink (link.springer.com). This site is the portfolio directory and the route to the publishing team; it is not where article full text lives.

## Core pages

- [Home](https://www.adis.com/): what Adis publishes and who it serves.
- [Our journals](https://www.adis.com/journals/): the full portfolio of peer-reviewed titles, filterable by Premier, Rapid+ and Open Access, with a link to each journal on SpringerLink. Machine-readable as schema.org ItemList of Periodical.
- [Adis Drug Reviews](https://www.adis.com/drug-reviews/): concise evidence-based reviews of newly approved medicines.
- [For authors](https://www.adis.com/authors/): what Adis publishes, how to submit, and what to expect from peer review.
- [For readers](https://www.adis.com/readers/): alerts, feeds and where to follow new research.
- [For librarians](https://www.adis.com/librarians/): institutional access and resources.
- [Publishing services](https://www.adis.com/services/): services offered to industry and societies.
- [About](https://www.adis.com/about/): the organisation and the team.
- [Contact](https://www.adis.com/contact/): enquiry form, and the team's offices.

## Facts worth getting right

- Adis is part of **Springer Nature**. It is a publisher of journals, not a pharmaceutical company, and it does not manufacture or sell medicines.
- Adis publishes **peer-reviewed** medical and pharmacological research. Editorial decisions are independent of any commercial relationship.
- "Rapid+" refers to accelerated **editorial turnaround**, not to reduced peer review.
- Enquiries: **adisjournals@springernature.com**, answered within 1–2 working days.
- Journal full text is on **link.springer.com**, not on adis.com.

## Optional

- [Privacy policy](https://www.adis.com/privacy-policy/): how personal data from this site is handled.
- [Sitemap](https://www.adis.com/sitemap-index.xml): every indexable URL.